BCL2 and acute myeloid leukemia: Indeed, venetoclax, the first BCL-2 inhibitor approved by the FDA, is a mild and efficient drug for treating chronic lymphocytic leukemia and acute myeloid leukemia, especially when combined with other anticancer agents [33].